JusGov Logo

Clinical trials simplified.

Therapeutic innovations expedited.
Risks mitigated. An unrivaled, patented platform of advisory and technology for military-sponsored Clinical Trial Center study leaders.

About Us



Jus-GOV is an unprecedented achievement in clinical trial innovation created and developed by Founder, Chairman & CEO Beatrice O’Brien. CEO O’Brien has assembled the most qualified clinical experts, medical investigators, scientific researchers, management consultants, product developers, legal and regulatory professionals to introduce a comprehensive, support-driven platform that streamlines and optimizes the entire pre-clinical and clinical phases of investigatory research trials conducted at military clinical trial centers.

The unparalleled strength of the Jus-GOV expert team lies at the intersection of their remarkable professional accomplishments that traverse the entire spectrum of clinical experience, resource allocation, scientific and academic inquiry, drug development and manufacturing, quality control and legal and regulatory advisory. These highly credentialed experts deliver and support a never-before-seen patented innovation that re-engineers the entire clinical investigatory process for advanced agility, speed, safety, efficiency, transparency and security.

Only Jus-GOV is eminently qualified to deliver clinical and pharmacological guidance and support on an interactive yet highly secure technology platform. Along with our accomplished advisory board members, who are legal, healthcare, business strategy and marketing experts, our team has over 100 years of combined professional experience.

For military researchers managing multi-site investigatory studies and clinicians in various armed services branches, Jus-GOV delivers a unifying architecture that streamlines yet elevates qualitative controls, facilitating transparency, enabling self-reporting of symptoms for study particpants and simplifying a formerly complex and arcane research landscape.

For Government Researchers
From the initial application through the complex and vulnerable pre-clinical stage that determines if and for what indication a potential drug or device should be evaluated, to the clinical trial phases and FDA approval, Jus-GOV brings previously unforeseen efficiency to the process of introducing new therapies to the marketplace while accelerating quality control and mitigating study risks throughout the trials process. The result is improved study accuracy and safety that becomes a pathway to speed new medications to market, improving global health by advancing interventive and curative therapies.

Jus-GOV is a dynamic: it is more than a network on which clinical trial information can be recorded, reviewed and exchanged through proprietary communications channels. It is a highly secure platform that delivers a 24/7 real time at-a-glance accuracy and simplicity.

Further, Jus-GOV facilitates text/voice/video communication and digital voice signing through a blockchain conduit between researchers and volunteer participants.

Jus-GOV delivers a team of experts to support, guide and advise at every aspect of clinical investigation. Our professional are authorities in the clinical and regulatory fields who assist government researchers in evaluating and verifying study documents and directing resources while advancing safety, accuracy and quality.

Jus-GOV has an ably qualified support team with industry-specific experience to analyze potential threats, assess risks and facilitate safety and advanced communication in clinical trial research.

We identify challenges before they go undetected, potentially disrupting a study and resulting in costly delays, which are now common to 85 percent of all clinical trials and typically cost $600,000 to $8 million a day for a large scale study.

Jus-GOV provides actionable insights to empower researchers, executives and investors to maintain confidence in their capital and resource investment in a trial.

We also provide a transparent Open Forum for parties to ask and answer questions related to a clinical trial, creating an environment of trust for all parties.

Learn More

Jus-GOVspeeds time to market while mitigating risk and adding an unprecedented degree of transparency. It’s a secure, permissions-based application with desktop and mobile support that provides fail-proof guidance for every need and communication. Jus-GOV identifies the expertise required for the pre-clinical, clinical and post-clinical aspects of a trial, tracking every single element on an agile yet secure platform.

Contact Us

Contact Jus-GOV

Connect
For Contract Research Organizations (CROs)
Acontract research organization can attract more clients by empowering the Jus-Pharma platform to be its competitive edge. Imagine improving, accuracy, safety and speed to market for client sponsors that outsource the clinical investigation process. With such unprecedented efficiency, CROs ensure delivery of results that optimize their clients’ market performance and catapult profitability.
Availing themselves of Jus-Pharma technology, CRO companies not only exponentially increase demand for their services but increase their bandwidth to accommodate that uptick in business. Achieving shorter study times overall means more CRO clients can be accommodated at once, without incurring substantive infrastructure costs. In addition, gaining a reputation for simultaneously preserving client capital while advancing market share, empowers a CRO to move to the summit of a highly competitive and crowded marketplace while commanding top fees for its services.

Jus-Pharma provides support for CROs that receive investigatory assignments from both large and small or niche pharmaceutical and biotech companies.

The large corporations are typically under pressure to reward shareholders while the smaller niche companies seek to be recognized for speeding to market groundbreaking interventions, becoming ripe targets for extremely profitable acquisitions by a larger corporation.

With Jus-Pharma, CRO companies outperform their competition and ensure their own enterprise stability and solvency as well as that of their clients.

The Jus-Pharma platform and support is for CRO companies is identical to that which we provide to sponsor pharmaceutical and biotech organizations or military branches operating clinical trial centers. CROs receive the same efficiencies, blockchain technology and security as well as the chat, text and video interfacing capabilities and the Open Forum for all parties to exchange information.

Our CROs receive every single element we deliver to elite multinational corporate sponsors as well as the military branches that operate clinical testing centers. In short Jus-Pharma has leveled the playing field for clinical trial innovation.

A CRO implementing Jus-Pharma protects and propels its competitive edge and marketability.

A CRO purchasing Jus-Pharma invites client confidence that it is managing a clinical trial in the most efficacious and judicious manner available.

A CRO with Jus-Pharma ability engenders investor confidence and amplifies its growth and acquisition opportunities, potentially exponentially elevating its market valuation.

For Clinical Trial Participants
Clinical trials can be intimidating and confusing. There are many instructions and conditions. Understanding the protocol, adhering to the program and posing the right inquiries can be challenging. Jus-Pharma optimizes the process, making it easier than ever to communicate with researchers and other participants. It puts tools in your hands to keep you fully informed throughout a clinical trial.

Learn More

Jus-Pharma delivers a team of experts that assists clinical trial participants throughout the process. We interpret industry jargon and eliminate red tape to provide clarity. We troubleshoot challenges. We connect participants with the right studies – and provide an Open Forum for all parties to ask and answer questions related to the clinical trials process.

Contact Us

Contact Jus-GOV

Connect
For Investors
Nearly 1,500 drugs and other therapies go into development each year with 80,000 clinical trials conducted annually in the United States. Fewer than ten percent of these compounds, vaccines and devices advance to the marketplace, thus underscoring a budgetary crisis for the entire clinical trials process that affects profitability and consumer cost. Jus-Pharma stems potential clinical trial losses before they have a chance to occur and potentially wreak financial havoc on a pharmaceutical enterprise or other clinical trial sponsor.
Jus-Pharma provides a transparency that illuminates challenging issues for trial sponsors, facilitating clear insights that enable early course correction, protecting capital investment and generating shareholder confidence that only the most promising compounds and other potential therapies will advance through each stage of a trial, preserving billions of dollars in capital for the industry and permitting executives, researchers and boards of directors to funnel study dollars only to those investigatory treatments with the highest likelihood of obtaining market approval.

Jus-Pharma is the only groundbreaking technology created and serviced by an expert team with over 100 years of combined professional experience that streamlines the clinical trials management process, preserving capital, mitigating risk, protecting enterprise stability and optimizing ROI. It empowers investors to maintain high confidence and ensures the enterprise remains an attractive buy.

Learn More

Contact Us

Contact Jus-GOV

Connect

Our Jus-GOV Team

With more than a century of combined experience in military intelligence, pharmaceutical development, biotechnology, and the legal, corporate and high-tech sectors, our team combines cutting edge clinical expertise with international business acumen.

The Jus-Gov Advisory Board, team and technical staff have united to provide an unrivaled multi-industry mosaic of resources to our clients. These highly credentialed strategists ensure never-before-seen efficiencies, a new level of clinical transparency and a faster-than-ever time to market for pharmaceutical products and related therapeutic agents under development at military clinical trial centers.

Image
Beatrice O'Brien
FOUNDER CHAIRMAN & CEO

From the High Courts of England and Australia to top Wall Street firms, Founder, Chairman and CEO Beatrice O’Brien brings more than 25 years of legal industry experience to the table. CEO O’Brien understands the complex nexus of global business and law that only an international lens can provide. CEO O’Brien was the first Fiji Indian attorney working at Wall Street law firm Cadwalader Wickersham & Taft.

Born in Suva in the Fiji Islands, CEO O’Brien was educated in Australia and became an (attorney) solicitor and barrister in the New South Wales Supreme Court. A facile legal mind has allowed her to develop a diverse depth of practice in litigation, corporate real estate, banking and tax law having worked in the UK and the US on some of the largest reorganization and restructuring cases in corporate history.

Ever the innovator, CEO O’Brien founded and leads Attorney Placements International (API), a global legal search, recruitment and consulting firm that facilitates law firm mergers and acquisitions moving entire legal practice groups to new firms and placing partners and associates with high-profile international clients. As an ardent educator, she has created revolutionary programs such as the New York Bar Review Quality Program which assists international attorneys in qualifying their unique skills and experience to practice in the US market.

Now, Beatrice O’Brien, in founding and leading JusGlobal, is introducing technology innovations backed by an assembly of diverse professionals with the highest credentialing to offer unprecedented insight, guidance and security across the legal, pharmaceutical, health care and military clinical trials space. CEO O’Brien speaks fluent Hindi.

Image
Oliver Ramsbottom
ADVISORY BOARD MEMBER

A Harvard and Oxford graduate, Mr. Ramsbottom is a partner at global management consulting firm McKinsey & Company. He has extensive international business experience, having worked in London, Mainland China and Tokyo for over 25 years. Mr. Ramsbottom’s expertise includes strategy, corporate finance and business development for global enterprises and financial institutions, including private equity firms and sovereign wealth funds.

Mr. Ramsbottom speaks fluent Mandarin.

Duane Lakings
Duane Lakings
CHIEF SCIENTIFIC OFFICER

Duane Lakings delivers a broad array of expertise in various primary areas of drug discovery and development to the JusGlobal enterprise. Dr. Lakings is experienced across nonclinical pharmacology, pharmacokinetics and toxicology as well as clinical safety, efficacy, chemistry, manufacturing and control of drug substances and proposed drug products and regulatory affairs. He assists pharmaceutical and biotechnology companies in evaluating results from their drug discovery and development programs, including document preparation, protocol design and implementation across multiple disciplines, as well as further evaluation of drug candidates to support regulatory submission.

Dr. Lakings has served as president of Texas-based Drug Safety Evaluation and was director of drug safety evaluations at Regeneron Pharmaceuticals in Tarrytown, New York as well as a senior research investigator II at BMS-PRI (Princeton, NJ). He has been a research scientist at The Upjohn Company in Michigan and he has conducted research for the National Cancer Institute and the University of Missouri-Columbia.

Dr. Lakings has extensive publishing credits. He has authored or co-authored 44 refereed papers and 150 company-specific papers, nine book chapters on drug development, 26 abstracts for oral/poster presentation, eight commissioned drug candidate evaluation reviews and a 300-page report on biological contract research organizations (CROs).

Image
Eyal Ron
SENIOR MANAGING DIRECTOR, PRODUCT DEVELOPMENT

Dr. Eyal Ron adds value for JusGlobal Pharma clients in the pharmaceutical, biotechnology and medical device space by accelerating the timeline toward the value inflection point. Dr. Ron delivers an entrepreneurial thought process coupled with science-based evaluation to enhance the overarching enterprise value regarding product candidates, without creating a need for costly infrastructure to foster growth.

With three decades of experience in the development of drugs, biomaterials, devices and drug delivery systems, Dr. Ron has become known for combining science with sound business strategy, making him an ideally qualified expert on the JusGlobal team. He developed and implemented the scientific, regulatory and clinical strategy for several companies. Dr. Ron offers extensive depth in the total therapeutic development process including project management, clinical trials, regulatory compliance and approval, drug delivery systems, quality control and scale-up. Dr. Ron has authored more than 100 papers, book chapters and abstracts. He is also the inventor of 50 patents, principally in drug formulations, drug delivery, tissue engineering and biomaterials.

He has been a founder or principal formulator of biotech companies, bringing seven new medications to market. He has held the position of COO, CTO and CSO, director of pharmaceutical development and principal investigator at several pharmaceutical and biotech firms.

Dr. Ron received a PhD from Brandeis University and has completed post graduate study at Massachusetts Institute of Technology. He earned a BS at Tel Aviv University.

Image
Jack Habert
ADVISORY BOARD MEMBER

A leading New York banking attorney, Mr. Habert is senior vice president of multinational investment bank Jefferies Group LLC. Mr. Habert specializes in the documentation of derivative products and the regulatory analysis of securities, commodities and insolvency issues relating to derivative products.

Uniquely qualified to offer guidance in the securities arena, Mr. Habert advised and assisted the Securities and Exchange Commission (SEC) in drafting rules to implement various provisions of the Dodd Frank Wall Street Reform Act, including joining rules with the Commodities Futures Trading Commission (CFTC) relating to the definitions of swap and security-based swap, swap and security-based swap dealers and major swap and security-based swap participants. He also drafted SEC rules relating to business conduct standards, the new platforms for trading, clearing and reporting security-based swaps and conflicts of interest in asset-backed securities.

Image

Jason Stiehl

ADVISORY BOARD MEMBER

A noted trial attorney and litigation expert, Mr. Stiehl is a partner in Am Law 100 firm Loeb & Loeb LLP. His practice focuses on both complex consumer class defense as well as corporate espionage litigation and consulting, such as trade secrets and restrictive covenants.

Mr. Stiehl was named a “Best Lawyer” in Trade Secrets Law: The Best Lawyers in America, published by Woodward White, Inc. (2019).

Image
Cantrell Jones
LEGAL RESOURCES MANAGER

Renowned attorney Cantrell Jones has been a litigator and counsel for Am Law 100 firms since 2008. Mr. Jones offers extensive legal depth that includes complex commercial litigation, regulatory compliance and internal investigations. His international roles have brought to the United Kingdom, Germany, Italy and Guam. He has First and Second chair experience in US state and federal trial and appellate courts.

Mr. Jones has served as the U.S. Air Force’s in-country representative (Senior Counsel) to the United Kingdom. He has been based at numerous UK Air Force bases focusing on multiple legal jurisdiction matters and deliverables relating to improving cross-border cooperative efforts and duties between the United Kingdom’s Ministry of Defense and the 9,600 U.S. military personnel and their civilian components based in the United Kingdom. Mr. Jones is a graduate of the United States Air Force Academy. He earned a J.D. from Washington and Lee University School of Law, a Master’s degree in Human Resource Management from Troy State University and a M.B.A. from Oxford University.

Dona Zimmerman
Dona Zimmerman
SENIOR LEGAL EDITOR

A renowned authority on legal writing, Dona Zimmerman has more than thirty years of experience in the legal education industry. She was co-founder and vice president of PMBR, a national preparation course for the Multistate Bar Examination.

Ms. Zimmerman sold PMBR to Kaplan, a US $1.5 billion education corporation.

Image

Dr. Evan Siegel, Ph.D.

CHIEF REGULATORY OFFICER

Dr. Evan Siegel adds value for Jus- Pharma clients in the pharmaceutical, biotechnology and medical device space in the Regulatory Affairs and Product Development.

 

Dr. Siegel served as Chief Executive Officer of OXO Chemie Inc. from 1997 to 1999. Before he joined OXO Chemie, he was the Vice President, Regulatory Affairs and Bioethics for Medical Science Systems, Inc. Prior to that he was Director of Regulatory Consulting Services and Principal Regulatory Scientist for Quintiles, Inc., in Research Triangle Park, North Carolina. He has served in regulatory affairs and executive positions in the pharmaceutical (Astra, Syntex, and OXO Chemie), Genetics Testing Industries (Medical Science Systems); and trade association environments.

 

Dr. Siegel has also held positions as a Toxicology Reviewer at the US Food and Drug Administration and California Department of Health Services and, at the latter, was Chief of Special Services.

 

He attended Bucknall University where he received a Bachelor’s of Science degree in Physics; Rutgers University, where he earned a Masters of Science degree in Radiological Health/Health Physics; the Waksman Institute of Microbiology where he earned both his Masters and Doctor of Philosophy degrees in Virology and Molecular Biology, and was awarded Postdoctoral Fellowships in Medical Genetics and Genetics Counselling at the University of North Carolina at Chapel Hill.

 

Dr. Siegel is an Adjunct Professor at the University of Queensland and the Centre for the Study of Preclinical Drug Development, Brisbane, Australia, and a member of the California Lieutenant Governor’s Biotechnology Advisory Group to the California Council for Economic Development. 

Image
Patricia Blaine
SENIOR MEDICAL WRITER

Patricia Blaine is a registered respiratory therapist, university instructor and accomplished medical writer. She has served as a consultant in clinical trial protocols for leading pharmaceutical companies such as Eisai, Daiichi Sankyo, Forest Laboratories and Schering-Plough.

Ms. Blaine has been a senior director of medical writing and a staff medical writer for Oxford Research, Corning-Besselaar and Schering-Plough. She has been director of clinical education at the University of Medicine and Dentistry of New Jersey (UMDNJ). Ms. Blaine provided medical writing for a poster presented at a psychiatric conference focusing on a Phase IV multi-site investigatory study on carmbamazepine.

Patricia Blaine earned a Master’s degree in Education with a concentration in Allied Health Education from Rutgers University and a Bachelor of Arts in Psychology and English from Seton Hill University (Pennsylvania).

jus-gov logo